PriceTargets.com logo

Forte Biosciences - FBRX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $72.50
  • Forecasted Upside: -5.35%
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$76.60 As of 07/31/2026 05:00 PM ET
▼ -0.38 (-0.49%)

This chart shows the closing price for FBRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Forte Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FBRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FBRX

Analyst Price Target is $72.50
▼ -5.35% Downside Potential
This price target is based on 7 analysts offering 12 month price targets for Forte Biosciences in the last 3 months. The average price target is $72.50, with a high forecast of $77.00 and a low forecast of $61.00. The average price target represents a -5.35% upside from the last price of $76.60.

This chart shows the closing price for FBRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 7 contributing investment analysts is to hold stock in Forte Biosciences. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/3/2026
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
7/2/2026
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
8/1/2026

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/28/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
7/28/2026BarclaysDowngradeOverweight ➝ Equal Weight$74.00 ➝ $77.00
7/27/2026EvercoreSet Target$77.00
7/27/2026TD CowenDowngradeStrong-Buy ➝ Hold
7/27/2026EvercoreDowngradeStrong-Buy ➝ Hold
7/27/2026Brookline Capital MarketsDowngradeStrong-Buy ➝ Hold
7/21/2026BarclaysInitiated CoverageOverweight$74.00
7/21/2026BarclaysInitiated CoverageOverweight$74.00
7/8/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
3/27/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/29/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/15/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/2/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/26/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/25/2025EvercoreInitiated CoverageOutperform$65.00
11/20/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
11/17/2025Chardan CapitalReiterated RatingBuy ➝ Buy$61.00
10/31/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/18/2025GuggenheimInitiated CoverageBuy$75.00
8/18/2025GuggenheimInitiated CoverageBuy$75.00
8/15/2025Chardan CapitalReiterated RatingBuy ➝ Buy$61.00
6/24/2025Chardan CapitalReiterated RatingBuy ➝ Buy$61.00
4/1/2025Chardan CapitalLower TargetBuy ➝ Buy$64.00 ➝ $61.00
1/21/2025TD CowenInitiated CoverageBuy
12/4/2024Chardan CapitalReiterated RatingBuy ➝ Buy$64.00 ➝ $64.00
11/15/2024Chardan CapitalBoost TargetBuy ➝ Buy$3.00 ➝ $64.00
8/19/2024Chardan CapitalReiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
4/8/2024LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$2.75
7/16/2023Chardan CapitalReiterated RatingNeutral
5/15/2023Chardan CapitalReiterated RatingNeutral
8/17/2022Chardan CapitalDowngradeBuy ➝ Neutral
9/3/2021FBR & Co.DowngradeBuy ➝ Hold
9/3/2021Truist FinancialDowngradeBuy ➝ Hold
9/3/2021LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral
9/3/2021Chardan CapitalDowngradeBuy ➝ Sell
9/3/2021B. Riley FinancialDowngradeBuy ➝ Neutral
(Data available from 8/1/2021 forward)

News Sentiment Rating

0.61 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2026
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2026
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2026
  • 20 very positive mentions
  • 27 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2026

Current Sentiment

  • 20 very positive mentions
  • 27 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Forte Biosciences logo
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Read More

Today's Range

Now: $76.60
Low: $76.54
High: $76.74

50 Day Range

MA: $31.75
Low: $15.67
High: $76.98

52 Week Range

Now: $76.60
Low: $9.10
High: $77.20

Volume

794,098 shs

Average Volume

2,297,478 shs

Market Capitalization

$1.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.85

Frequently Asked Questions

What sell-side analysts currently cover shares of Forte Biosciences?

The following sell-side analysts have issued reports on Forte Biosciences in the last year: Barclays PLC, Brookline Capital Markets, Chardan Capital, Evercore Inc, Guggenheim, TD Cowen, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for FBRX.

What is the current price target for Forte Biosciences?

0 Wall Street analysts have set twelve-month price targets for Forte Biosciences in the last year. Their average twelve-month price target is $72.50, suggesting a possible downside of 5.4%. Barclays PLC has the highest price target set, predicting FBRX will reach $77.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $61.00 for Forte Biosciences in the next year.
View the latest price targets for FBRX.

What is the current consensus analyst rating for Forte Biosciences?

Forte Biosciences currently has 1 sell rating, 4 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in FBRX, but not buy more shares or sell existing shares.
View the latest ratings for FBRX.

What other companies compete with Forte Biosciences?

Other companies that are similar to Forte Biosciences include Viking Therapeutics, Catalyst Pharmaceuticals, Tango Therapeutics, Denali Therapeutics and Adaptive Biotechnologies. Learn More about companies similar to Forte Biosciences.

How do I contact Forte Biosciences' investor relations team?

Forte Biosciences' physical mailing address is 1124 W CARSON STREET MRL BUILDING 3-320, TORRANCE CA, 90502. The company's listed phone number is (310) 618-6994 and its investor relations email address is [email protected]. The official website for Forte Biosciences is www.fortebiorx.com. Learn More about contacing Forte Biosciences investor relations.